ClinicalTrials.gg
Status unknownNCT04989114Updated Aug 4, 2021

Nasal Bubble Continuous Positive Airway Pressure in Reducing Respiratory Distress in Children With Bronchiolitis

An interventional study of nasal continuous positive airway pressure in Bronchiolitis Acute Viral, Bronchiolitis and Bronchiolitis Acute, sponsored by ameer asadullah gull. Status unknown at 1 site in Pakistan. Open to participants aged 2 Months to 2 Years. Per ClinicalTrials.gov, last updated 2021-08-04.

Primary conditionBronchiolitis, ViralRegistry: BronchiolitisReclassifiedWhy we changed it
Registry
Bronchiolitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchiolitis, Viral
Why
  1. The study's listed conditions name Bronchiolitis, Viral, a narrower term within Bronchiolitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ameer asadullah gull · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Sep 2020, registered Jul 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
2 Months to 2 Years
Sex
All
01

Study summary

This study is designed to assess the effectiveness of nasal continuous positive airway pressure in reducing respiratory distress in children with bronchiolitis

Read the detailed description

In this study, after taking consent from caretakers, patients of brochiolitis will be randomly assigned to either a standard care group or a nasal continuous positive airway pressure group. Both groups will be followed for respiratory distress. Respiratory distress will be compared by using Seattle sore of respiratory distress.

02

Conditions studied

  • Bronchiolitis Acute Viral
  • Bronchiolitis
  • Bronchiolitis Acute
  • Bronchiolitis, Viral
  • Nasal Continuous Positive Airway Pressure

Browse trials for

03

In context

Bronchiolitis, Viral Reclassified

30 studies on the registry are indexed under Bronchiolitis, Viral; 2 are open to participants now.

This study's planned enrollment of 96 is above the median of 85 across 25 interventional studies indexed under Bronchiolitis, Viral.

Browse Bronchiolitis, Viral studies →

Lead sponsor

This is the only study on the registry with ameer asadullah gull as lead sponsor.

Compared within Bronchiolitis, Viral, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bronchiolitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
2 Months to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children presenting with history of cough, and tachypnea and wheezing on clinical examination

Exclusion criteria

Exclusion Criteria:

  • Patients needing mechanical ventilation at the time of admission
  • Patients whose caretakers refuse written
  • Patients having consolidation on chest X-Ray
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • No intervention
    standard care

    In this arm, oxygen inhalation will be provided without positive end expiratory pressure

  • Experimental
    nasal continuous positive airway pressure

    In this arm, positive end expiratory pressure will be provided by nasal continuous positive airway pressure

    Device: nasal continuous positive airway pressure

Interventions

  • Devicenasal continuous positive airway pressure

    positive end expiratory pressure will be applied by nasal continuous positive airway pressure

06

What researchers measure

Primary outcomes

  1. reduction in seattle score

    seattle score will be noted and compared for both groups

    Time frame: after 12 hours

07

Study locations

1 of 1 sites recruiting
  • Mayo Hospital
    Lahore, Punjab 54000, Pakistan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Sep 2021, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Aug 4, 2021
StartActual
Sep 6, 2020
Primary completionEst.
Sep 5, 2021
CompletionEst.
Sep 5, 2021
Last update
Aug 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04989114
Lead sponsor
ameer asadullah gull
Collaborators
King Edward Medical University
Responsible party
ameer asadullah gull (Postgraduate Resident Pediatric Medicine, King Edward Medical University) — Sponsor-investigator
First posted
Aug 4, 2021
Start date
Sep 6, 2020
Primary completion
Sep 5, 2021 (estimated)
Completion
Sep 5, 2021 (estimated)
Last update
Aug 4, 2021

Study contacts

Ameer Asadullah Gull, MBBS
Contact
hellowgull@yahoo.com
00923084860184
Muhammad Haroon Hamid, MBBSFCPSFRCS
Contact
haroonr5@yahoo.com
00923008880916
Muhammad Haroon Hamid, MBBSFCPSFRCS
principal investigator · King Edward Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion